David Pellicane
Illumivaption Inc. d/b/a Nashville Vapor
2139 Gallatin Pike N
Madison , TN 37115
United States
david@nashvillevapor.com
orders@nashvillevapor.comIssued Oct 7, 2021Center for Tobacco Products
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.
Violations1
Issue DateOct 7, 2021
Product TypeTobacco
StatusClosed
Closeout LetterJul 14, 2022
Letter Details
Firm
Illumivaption Inc. d/b/a Nashville Vapor
Location
David Pellicane
Illumivaption Inc. d/b/a Nashville Vapor
2139 Gallatin Pike N
Madison , TN 37115
United States
david@nashvillevapor.com
orders@nashvillevapor.com
FEI Number
N/A
Country
United States
Issue Date
October 07, 2021
Issuing Office
Center for Tobacco Products
Product Type
Tobacco
Status
Closed
Closeout Letter
July 14, 2022
Summary
Illumivaption Inc. d/b/a Nashville Vapor was cited for manufacturing and selling e-liquid tobacco products without required premarket authorization orders, which are mandated for "new tobacco products" under the Family Smoking Prevention and Tobacco Control Act. The company's e-liquids, offered for sale through their website, were found to be subject to FDA jurisdiction as deemed tobacco products but lacked the legally required marketing authorization to remain in commerce. The FDA determined these products violated the Federal Food, Drug, and Cosmetic Act by failing to comply with premarket review requirements that became effective August 8, 2016.
Illumivaption Inc. d/b/a Nashville Vapor FDA Warning Letter, October 7, 2021